Posts filed under ‘Infecciones en piel y tej blandos’

Highlights From Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

Infectious Diseases in Clinical Practice May 2011 V.19 N.3 P.207-20

Clinical Guidelines

File, Thomas M. Jr

Recently, the Infectious Diseases Society published evidence-based guidelines for the treatment of methicillin-resistant Staphylococcus aureus infections.

The guideline discusses the management of a variety of infections including skin infections, bacteremia and endocarditis, pneumonia, and osteomyelitis and joint infections.




December 7, 2018 at 9:28 am

Managing an Elusive Pathogen: Treatment of Methicillin-Resistant Staphylococcus aureus Infections in a Variety of Care Settings

Infectious Diseases in Clinical Practice May 2011 V.19 N.3 P.150-155

NFID Clinical Updates

Poretz, Donald M.; Rehm, Susan J.

Methicillin-resistant Staphylococcus aureus (MRSA) infections continue to be a major problem both within hospitals (hospital-acquired MRSA) and increasingly in community settings (community-acquired MRSA), leading to well-publicized media reports and, as a result, greater public awareness of this problem.

Clinically, it is difficult to distinguish between a MRSA and a methicillin-sensitive S. aureus skin and soft tissue infection, and this should be taken into consideration when initiating empiric therapy.

There are several oral and intravenous antibiotics available to treat MRSA infections, some of which are inexpensive, whereas others are extremely costly; all have potential adverse effects and possible drug-drug interactions with which the prescriber should be familiar.

Careful monitoring of patients who receive outpatient intravenous antibiotics and an understanding of various intravenous devices and their associated possible complications in addition to knowledge of the economics involved are essential to make cost-effective decisions.



December 7, 2018 at 9:24 am

Outbreak of Tattoo-Associated Nontuberculous Mycobacterial Skin Infections.

Clinical Infectious Diseases

Isabel Griffin, MPH  Ann Schmitz, DVM  Christine Oliver  Scott Pritchard, MPH Guoyan Zhang, MD, MPH  Edhelene Rico, MPH  Emily Davenport  Anthoni Llau, PhD Emily Moore, MPH  Danielle Fernandez, MPH 


On April 29, 2015, the Florida Department of Health in Miami-Dade County (DOH-Miami-Dade) was notified by a local dermatologist of three patients with suspect nontuberculous mycobacterial (NTM) infection after receiving tattoos at a local tattoo studio.


DOH-Miami-Dade conducted interviews and offered testing, described below, to tattoo studio clients reporting rashes. Culture of clinical isolates and identification were performed at the Florida Bureau of Public Health Laboratories (BPHL). Characterization of NTM was performed by the Centers for Disease Control and Prevention (CDC) and the United States Food and Drug Administration (FDA), respectively. Whole-genome sequencing (WGS) and single-nucleotide polymorphism (SNP) analyses were used to construct a phylogeny among 21 Mycobacterium isolates at FDA.


Thirty-eight of 226 interviewed clients were identified as outbreak-associated cases. Multivariate logistic regression revealed individuals who reported grey tattoo ink in their tattoos were 8.2 times as likely to report a rash [95% CI: 3.07—22.13]. Multiple NTM species were identified in clinical and environmental specimens. Phylogenetic results from environmental samples and skin biopsies indicated that two M. fortuitum isolates (greywash ink and a skin biopsy) and 11 M. abscessus isolates (five from the implicated bottle of greywash tattoo ink, two from tap water, and four from skin biopsies) were indistinguishable. In addition, M. chelonae was isolated from five unopened bottles of greywash ink provided by two other tattoo studios in Miami-Dade County.


WGS and SNP analyses identified the tap water and the bottle of greywash tattoo ink as the sources of the NTM infections.



November 28, 2018 at 8:19 am

Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02551-17.

Goldstein EJC1,2, Citron DM3, Tyrrell KL3, Leoncio E3, Merriam CV3.


Omadacycline was tested against 125 isolates recovered from infected cat and dog bites in humans.

Its activity was similar to that of other compounds in the tetracycline class, and it was active against strains exhibiting tetracycline resistance.

Against anaerobic isolates, resistance to tetracyclines was more prominent and omadacycline was the most active of the group.

All isolates had omadacycline MICs of <1 μg/ml, with the exception of Eikenella corrodens, which showed reduced susceptibility to the entire tetracycline group.


November 18, 2018 at 11:58 am

In Vitro Activities of Omadacycline and Comparators against Anaerobic Bacteria.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e00047-18.

Stapert L1, Wolfe C1, Shinabarger D1, Marra A2, Pillar C1.


Omadacycline (OMC), a broad-spectrum aminomethylcycline, has shown clinical efficacy in anaerobic acute bacterial skin and skin structure infections (ABSSSI) and in animal models of intra-abdominal anaerobic infections.

Here, the in vitro activity of OMC against clinically relevant anaerobes was similar to that of tigecycline, with MIC90 values of 1 to 8 μg/ml against Bacteroides spp., 0.5 μg/ml against Clostridium difficile, Prevotella spp., and Porphyromonas asaccharolytica, 1 μg/ml against Peptostreptococcus spp., and 16 μg/ml against Clostridium perfringens.


November 18, 2018 at 11:56 am

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02327-17.

Pfaller MA1,2, Huband MD3, Shortridge D1, Flamm RK1.


Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016.

Omadacycline was active against Staphylococcus aureus (MIC50/MIC90, 0.12/0.25 mg/liter), including methicillin-resistant S. aureus (MRSA); streptococci (MIC50/MIC90, 0.06/0.12 mg/liter), including Streptococcus pneumoniae, viridans group streptococci, and beta-hemolytic streptococci; Enterobacteriaceae, including Escherichia coli (MIC50/MIC90, 0.5/2 mg/liter); Haemophilus influenzae (MIC50/MIC90, 1/1 mg/liter); and Moraxella catarrhalis (MIC50/MIC90, 0.25/0.25 mg/liter).

Omadacycline merits further study in serious infections where resistant pathogens may be encountered



November 18, 2018 at 11:55 am

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01487-17.

Bundrant LA1, Tzanis E2, Garrity-Ryan L3, Bai S2, Chitra S2, Manley A2, Villano S2.


Omadacycline, a first-in-class aminomethylcycline antibiotic, is related to tetracyclines but is structurally modified to circumvent mechanisms of resistance to tetracyclines.

Omadacycline demonstrates potent activity against a broad range of pathogens, including drug-resistant strains, and is in late-stage development for treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.

Previous studies support an intravenous-to-oral transition regimen with 300-mg once-daily oral dosing.

This phase 1 study investigated the pharmacokinetics and safety/tolerability of multiple oral omadacycline doses higher than 300 mg.

Using a 3-period crossover design, healthy adults were randomized to receive oral omadacycline at 300, 450, and 600 mg in variable sequence (n = 26) or placebo (n = 7) once daily for 5 consecutive days per period. In plasma, omadacycline maximum concentration and total exposure increased with increasing dose but were less than dose proportional.

The kinetics of omadacycline plasma accumulation were similar between dose levels; exposure on day 5 was ∼50% higher than that on day 1.

Omadacycline plasma concentrations on day 1 of 450-mg dosing were similar to those on day 5 of 300-mg dosing.

All doses were generally well tolerated, but the 600-mg dose was associated with more gastrointestinal adverse events.


November 18, 2018 at 11:54 am

Older Posts


December 2018
« Nov    

Posts by Month

Posts by Category